ADARx Pharmaceuticals, Inc.

Overview

Compare with another stock.

• TickerADRX on Nasdaq¹
• IndustryPharmaceutical Preparations¹
• HeadquartersSan Diego, California¹
• Incorporated inDE²
• Business address5871 Oberlin Drive, Suite 200, San Diego, Ca 92121²
• Filer category, Emerging growth company²
• Legal formCorporation

See how the biggest companies compare on our leaderboards

Corporate structure

ADARx Pharmaceuticals, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

Leadership

Who has led ADARx Pharmaceuticals, Inc., and when. Pick a name to see everywhere that person has worked.

• Chief financial officerRyan Fisk Sep 24, 2026 to now³

Named in SEC Form D filings

People the company listed in its private-offering notices.

• Executive OfficerRui Zhu named Jan 26, 2023 to Aug 10, 2023¹¹
• Executive Officer, Director, PromoterZhen Li named Jan 26, 2023 to Aug 10, 2023¹¹
• DirectorChen Yu named Aug 10, 2023¹¹
• DirectorJudith Li named Jan 26, 2023 to Aug 10, 2023¹¹
• DirectorLorence Kim named Jan 26, 2023 to Aug 10, 2023¹¹
• DirectorRicky Sun named Aug 10, 2023¹¹
• DirectorSheila Gujrathi named Jan 26, 2023 to Aug 10, 2023¹¹
• DirectorYuan (Eliza) Sun named Jan 26, 2023 to Aug 10, 2023¹¹

Timeline

1. Sep 28, 20268-K Unregistered sale of shares; Bylaws or fiscal year changed; Other events¹²

Filings

41 filings to the SEC since October 2021: 1 major events, 24 insider forms, 3 large holders, 2 private raises, 11 other. The latest 20:

1. Oct 5, 2026SCHEDULE 13D EDGAR
2. Oct 2, 2026SCHEDULE 13D EDGAR
3. Oct 1, 2026SCHEDULE 13G EDGAR
4. Sep 30, 20264 EDGAR
5. Sep 30, 20264 EDGAR
6. Sep 30, 20264 EDGAR
7. Sep 29, 20264 EDGAR
8. Sep 29, 20264 EDGAR
9. Sep 29, 20264 EDGAR
10. Sep 28, 20264 EDGAR
11. Sep 28, 20264 EDGAR
12. Sep 28, 20264 EDGAR
13. Sep 28, 20264 EDGAR
14. Sep 28, 20264 EDGAR
15. Sep 28, 2026S-8 EDGAR
16. Sep 28, 20268-K EDGAR
17. Sep 28, 2026424B4 EDGAR
18. Sep 24, 2026EFFECT EDGAR
19. Sep 24, 20263 EDGAR
20. Sep 24, 20263 EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

5 open-market trades by officers, directors and large owners since October 2021: 5 buys and 0 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• SR ONE CAPITAL MANAGEMENT, LLCSCHEDULE 13D, 1 filing Oct 5, 2026¹³
• ORBIMED ADVISORS LLCSCHEDULE 13D, 1 filing Oct 2, 2026¹⁴
• BCLS Fund III Investments, LPSCHEDULE 13G, 1 filing Oct 1, 2026¹⁵

Money raised

Private offerings the company reported to the SEC on Form D.

1. Aug 2, 2023Raised $200 million in a private offering of equity Form D: 28 investors so far Form D
2. Jan 26, 2023Raised $46 million in a private offering of equity Form D: 10 investors so far Form D

SEC filer profile

How ADARx Pharmaceuticals, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARADARx Pharmaceuticals, Inc.¹
• CIK0001802369
• Employer ID (EIN)84-4145188¹
• Filer status<br>emerging growth company¹
• Incorporated inDelaware¹
• Fiscal year endsDecember 31¹
• Industry code (SIC)2834 Pharmaceutical Preparations¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business address5871 Oberlin Drive, Suite 200, San Diego, CA 92121¹
• Phone858-283-9472¹
• On EDGAR sinceFeb 6, 2020¹
• Filings46 in all: 3 (13), 4 (11), D (7), S-1/A (2), SCHEDULE 13D (2), 424B4 (1), 8-A12B (1), 8-K (1)¹
  All 16 form types

  CERT (1), DRS (1), DRS/A (1), EFFECT (1), S-1 (1), S-1MEF (1), S-8 (1), SCHEDULE 13G (1)

• Latest filingsLatest 8-K (8-K) Sep 28, 2026